CB Exo A 600
Alternative Names: CB-Exo-A600Latest Information Update: 03 Apr 2026
At a glance
- Originator Carrier Biomed (Suzhou)
- Class Mesenchymal stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Alzheimer's disease
Most Recent Events
- 10 Mar 2026 Carrier Biomed plans a phase I/II trial for Alzheimer's disease (Treatment-experienced) in China (intranasal) in March 2026 (NCT07457125)
- 09 Mar 2026 Preclinical trials in Alzheimer's disease in China (Intranasal) before March 2026